Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -5.65% | -13.02% | +9.15% |
Financials (USD)
Sales 2024 * | 24.2M | Sales 2025 * | 83.79M | Capitalization | 604M |
---|---|---|---|---|---|
Net income 2024 * | -200M | Net income 2025 * | -201M | EV / Sales 2024 * | 25 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.2 x |
P/E ratio 2024 * |
-2.18
x | P/E ratio 2025 * |
-2.44
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | -5.65% | ||
1 week | -13.02% | ||
Current month | +8.44% | ||
1 month | +1.21% | ||
3 months | -33.47% | ||
6 months | +54.63% | ||
Current year | +9.15% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +11.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 1.67 | -5.65% | 4,592,128 |
24-05-20 | 1.77 | 0.00% | 2,576,152 |
24-05-17 | 1.77 | -3.80% | 1,847,436 |
24-05-16 | 1.84 | -5.15% | 1,616,085 |
24-05-15 | 1.94 | +1.04% | 1,470,630 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.15% | 604M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- LXRX Stock